Promising patient trials surrounding the medication Retatrutide , specifically the 120mg formulation referred to as ZPHC, indicate a considerable impact on physique loss and associated health conditions . Experts anticipate that this combined acting , targeting both GLP-1 and GIP receptors , has the potential to represent a noteworthy improvement